First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
Over 70 per cent of the world’s population have no access to MRI scanners and the situation is not that encouraging in India where there are only 0.4 MRI scanners per thousand people
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The lab will offer over 4,000 clinical tests and profiles and can conduct over 20,000 sample tests per month.
In comparison to traditional open-heart surgery, which involves opening up the chest by splitting the breastbone, da Vinci Xi's innovative technology allows for complex cardiovascular surgeries to be performed through smaller incisions and precise motion control
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
At present 18 per cent of the local pharmaceutical market is under government's price control
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across 10 sites in India
Subscribe To Our Newsletter & Stay Updated
